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Spinal muscular atrophy (SMA) is a rare genetic diseasecaused by the mutation or deletion of the survival of motorneuron 1 (SMN1) gene. SMA is characterized by progressive
degeneration of spinal motoneurons, leading to muscle weakness
and atrophy. Humans carry two nearly identical copies of the
SMN genes: SMN1 and SMN2. SMN1 expresses full-length SMN
protein, whereas SMN2 exon 7 is predominantly skipped, due to a
C-to-T transition at position 6 (C6U in the transcript) of exon 7,
such that the mRNA is translated into a truncated and unstable
protein1, 2. Regulation of SMN2 exon 7 splicing is one of the best
studied alternative splicing processes, and is an attractive ther-
apeutic target. With the rise in genomic sequencing, the number
of identiﬁed mutations affecting splicing has increased to over
half of all disease-causing mutations3. Thus, approaches targeting
splicing are becoming more relevant for drug development to
treat splicing related disorders.
Alternative splicing in eukaryotes evolved to increase the
coding potential of the genome by allowing the expression of
multiple mRNA isoforms from a single gene. Splicing is a process
that requires ﬁve snRNAs and more than 100 proteins to
recognize sequence-speciﬁc sites and for catalysis. Additional
regulatory splicing factors inﬂuence the extent of exon inclusion
and intron excision. Splicing can be controlled individually for
each gene and portions thereof, including decisions on exon
inclusion, exon skipping, intron retention, recruitment of alter-
native 5′ and 3′ splice sites (5′ss and 3′ss), and mutually exclusive
exons4. In general, intron removal is performed by the spliceo-
some, whose assembly involves recognition of the 5′ss, the 3′ss
and the branch point sequence by U1 snRNP, U2AF, and
U2 snRNP, respectively, among other factors. Several steps in this
process may fail as a result of mutations in the coding sequence of
an exon.
Various mechanisms have been proposed for how the C6U
transition in the SMN2 gene leads to exon 7 skipping, including
disruption of an exonic splicing enhancer (ESE, recognized by
SRSF1/SF2/ASF), gain of an exonic splicing silencer (recognized
by hnRNP A1), and/or strengthening of an inhibitory stem–loop
structure (TSL1) at the 3′ss of exon 75–8. The stem–loop structure
TSL2 at the 3′ end of exon 7 is also thought to partially sequester
the 5′ss of exon 79, 10.
SMN2 exon 7 comprises three ESE regions, named for their
ability to promote exon 7 inclusion. The ESE2 region of SMN2
exon 7 is particularly relevant for this study. A variety of trans-
acting factors were found to interact with exon 7. Tra2-β1, for
example, is a splicing activator that interacts with a GAA motif in
ESE2, with the G residue at position 22 being especially critical
for stimulating exon 7 inclusion11. Overexpression of the splicing
proteins SRSF9 (SRp30c) and hnRNP G, which interact with
Tra2-β1, also promotes exon 7 inclusion. HnRNP G interacts
with an A tract sequence upstream of the Tra2-β1 binding site12.
Although Tra2-β1 has been recently shown to be dispensable13,
hnRNP G and Tra2-β1 in combination are thought to strongly
enhance the efﬁciency of exon 7 inclusion12, 14. These and other
observations suggest that SMN2 alternative splicing is coordi-
nated by multiple sets of RNA–protein (RNP) interactions that
likely involve higher-order folding of the pre-mRNA.
Several approaches that therapeutically target alternative spli-
cing of SMN2 are currently in various stages of development.
These approaches range from an antisense oligonucleotide
(SPINRAZA®) that has already received marketing approval to
small molecules, all of which promote exon 7 inclusion and
increase functional SMN protein levels. NVS-SM1 is a small
molecule SMN2 splicing modiﬁer that acts speciﬁcally at the 5′ss
of exon 7 to enhance binding afﬁnity of the U1 snRNP, stabilizing
the imperfect RNA helix formed by SMN2 pre-mRNA and the
U1 snRNP complex15.
In 2014, we reported the identiﬁcation of highly selective
SMN2 splicing modiﬁers16. In the present study, we investigate
their mechanism of action and ﬁnd that the SMN-C class of
molecules function via a speciﬁc interaction with an
mRNA–protein complex comprising a primary splice site, a
downstream exonic splicing enhancer region, and trans-acting
splicing proteins at these locations on the mRNA. Combining
different techniques in RNA biology and protein chemistry,
including in vitro splicing assays, chemical proteomics, nuclear
magnetic resonance (NMR), and surface plasmon resonance
(SPR), we are able to identify that these small molecules function
via interaction with a tertiary RNA structure comprising the ESE2
region of exon 7, and an RNA helix (formed by the 5′ss in intron
7 and the 5′ terminus of U1 snRNA) that binds the U1 snRNP
complex. This interaction of small molecules with the
mRNA–protein complex is critical for the high selectivity of the
small molecules for SMN2, which is higher than that of com-
pounds that interact only at the 5′ss site. Such selectivity of small
molecules for complex, quaternary RNP structures has implica-
tions for therapeutic development in other diseases, potentially
relevant in cases of previously considered undruggable small
molecule targets.
Results
SMN2 splicing modiﬁers modulate pre-mRNA splicing. We
ﬁrst hypothesized that the SMN2 splicing modiﬁers might func-
tionally interact with the splicing process in cells. We therefore
investigated the activity of SMN-C316 in a whole cell assay using
SMA type 1 patient ﬁbroblasts in combination with the phar-
macological blockade of biological processes from DNA tran-
scription to protein translation (Supplementary Fig. 1). Inhibitors
of spliceosome assembly on pre-mRNA, with pharmacological
inhibitors such as isoginkgetin17 or pladienolide B18, strongly
reduced SMN-C3 activity, affecting both full-length and exon-7-
lacking SMN2 mRNA to similar degrees (Fig. 1a, b). In contrast,
blocking polyadenylation with cordycepin19 (Fig. 1c) or inhibi-
tion of protein translation by puromycin20 (Supplementary
Fig. 2C) did not affect SMN-C3 activity. Treatment with acti-
nomycin D or α-amanitin, inhibitors of RNA polymerase II21,
reduced SMN-C3 activity (Supplementary Fig. 2A, B) and also
decreased baseline amounts of SMN2 pre-mRNA (Supplementary
Fig. 2D, E); this is known to generally occur concurrently with
RNA polymerase II transcription22. These data indicate that the
SMN2 splicing modiﬁers act on the pre-mRNA splicing process
but not on transcription or translation.
To further conﬁrm the results with the classic pharmacological
inhibitors, we used cell-free HeLa nuclear extracts and performed
in vitro splicing with the structurally similar pharmacophore
splicing modiﬁers, SMN-C3 and SMN-C5 (Supplementary
Fig. 2G). SMN-C5 showed a concentration-dependent correction
of SMN2 splicing to increase exon 7 inclusion (Supplementary
Fig. 2G), whereas SMN-C3 did not show a change in this
experimental assay. Given the similar pharmacophore of SMN-
C5 and SMN-C3 and very similar potency in cellular assays (EC50
17 nM for SMN-C3 (Supplementary Fig. 2A), 15 nM for SMN-C5
(Supplementary Fig. 3A), the result was unanticipated but
explicable by the particular physicochemical properties of the
molecules. SMN-C5 has a much higher permeability (assessed in
the PAMPA assay) compared to SMN-C3, as well as a much
lower amphiphilicity, two properties that may explain the
difference in potency especially at higher concentration in cell-
free assays such as the in vitro splicing assay.
To further understand this effect at the molecular level, we
utilized chemical proteomics to identify proteins that may bind to
the SMN2 splicing modiﬁers. We generated active and inactive
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ligands based on the structure of SMN-C5. This was initiated
ﬁrstly because of the better physicochemical properties of SMN-
C5, and secondly due to the chemical structure of SMN-C5,
which as opposed to SMN-C3, is amenable to side group
modiﬁcations required for ligand immobilization without losing
biological activity (Supplementary Fig. 3). For pull-down
experiments, either the Active (SMN-C6) or the Inactive (SMN-
C7) derivatives of SMN-C5 were immobilized on Sepharose
beads. Using cellular extracts from SMA type 1 patient ﬁbroblasts,
a strong and RNase-sensitive enrichment of proteins with the
active, but not the inactive ligand, was observed (Fig. 1d). We
identiﬁed 430 proteins enriched on afﬁnity matrices with the
active vs. the inactive ligand (p-adj< 0.05; log2 fold change> 1.5,
Supplementary Table 1). Following pathway-based enrichment
analyses of the chemical proteomics data, a strong enrichment of
proteins involved in RNA splicing was observed (Fig. 1e). All ﬁve
major spliceosomal snRNPs were represented and speciﬁcally
enriched with the active vs. the inactive ligand (Supplementary
Fig. 4A, B). In addition, mature mRNAs of SMN2 and STRN3, the
two major hits identiﬁed previously16, were enriched in cellular
extracts incubated with the active ligand (Supplementary Fig. 4C).
Taken together, these data suggest that the splicing modiﬁers
inﬂuence alternative splicing by directly interacting with the
splicing machinery, in the presence of RNA.
SMN2 splicing modiﬁers bind to the U1 snRNA:5′ss duplex.
The 5′ss in the SMN2 gene is inherently weak at interacting with
the U1 snRNA component of U1 snRNP23. Recently published
data suggested that NVS-SM1, a different class of compound,
increases the binding afﬁnity of U1 snRNP for the 5′ss of exon
715, 16. Thus, we investigated whether SMN-C5 interaction with
5′ss directly or indirectly inﬂuences the binding afﬁnity of spli-
ceosomal U1 snRNP. For this purpose, the binding potential to
the 5′ss of three splicing modiﬁers, SMN-C5 (Active), SMN-C7
(Inactive), and NVS-SM1 was monitored in the presence of an
SMN2 pre-mRNA fragment and U1 snRNA using solution-
state1H NMR. Binding of all three compounds induced changes
in the resonance of the RNA duplex formed by the 5′-terminus of
U1 snRNA and the 5′ss of SMN2 pre-mRNA (Supplementary
Fig. 5A, B). Whereas SMN-C7 and NVS-SM1 mainly bound
downstream (further into the intron) of the consecutive pseu-
douridine:adenine pairs in the U1 snRNA:5′ss duplex, SMN-C5
bound preferentially upstream, in the region where the last ade-
nine of exon 7 (which does not ﬁt the 5′ss consensus) is pro-
truding, a spot known for its ability to lower the splicing
efﬁciency of SMN exon 7 (Fig. 2a, b)7, 23–25.
According to the chemical-shift perturbations we observed,
SMN-C5 targets the major groove of the RNA duplex between the
5′ss SMN2 fragment and U1 snRNA (Fig. 2b, Supplementary
Fig. 5D) and induces the broadening of one imino signal, in line
with binding in the proximity of the base pairs (Supplementary
Fig. 5A). In the context of intact U1 snRNP, the U1 snRNA:5′ss
duplex is stabilized by the zinc ﬁnger domain of U1-C, a subunit
of U1 snRNP, which contacts both RNA strands via their ribose-
phosphate backbone26, 27. We performed NMR titration on the
same RNA duplex already bound by the zinc ﬁnger domain of
U1-C. Very similar chemical-shift changes of the RNA were seen
upon addition of SMN-C5, consistent with SMN-C5 binding in
the absence of protein, and without affecting U1-C binding
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Fig. 1 Small molecule splicing modiﬁers act directly on the RNA splicing process. a, b, c RT-PCR analysis of SMN2mRNA FL and Δ7 relative transcript levels
in SMA type 1 patient ﬁbroblasts. SMN-C3 compound activity after 6 h treatment was investigated in the presence or absence of inhibitors of splicing or
polyadenylation, namely 50 µM isogingketin a, 100 nM pladienolide B b, or 40 µM cordycepin c. d Coomassie gel after chemical proteomics showing
proteins pulled down in the presence of Active vs. Inactive compound, as well as after RNase treatment. The full gel is illustrated in Supplementary Fig. 2H.
e Pathway enrichment analysis of Active compound (SMN-C6), suggesting highest enrichment of mRNA splicing complexes by Active, together with other
categories. Removal of ribosomal proteins from the list conﬁrmed a selective enrichment of proteins involved in mRNA splicing or nucleotide binding. Data
in a, b, c represent means± standard error of the mean (SEM) of at least nine independent assessments per concentration
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(Supplementary Fig. 5C). The binding interfaces of SMN-C5 and
U1-C are located on opposite sites around the invariant GU motif
of the 5′ss (Fig. 2b). Taken together, the NMR analyses revealed
that SMN-C5 binds the U1:5′ss duplex at a different site than
SMN-C7 or NVS-SM1, and its binding site is not affected by the
presence of the U1-C zinc ﬁnger.
ESE2 interactions determine splicing modiﬁers speciﬁcity.
Having conﬁrmed the binding of both classes of SMN2 splicing
modiﬁers to the U1 snRNA:5′ss duplex—albeit at different
positions—and given the high overlap of the pharmacophores of
SMN-C class compounds and NVS-SM1 (Fig. 3a), we aimed to
understand the differences in their selectivity for global splicing
events and transcriptional changes15, 16. We performed
transcriptome-wide sequencing of RNA from type 1 SMA patient
ﬁbroblasts treated with SMN-C3 at ~50 times the EC50 (500 nM,
Supplementary Fig. 6A) or NVS-SM1 at ~5 times the EC50
(24 nM, Supplementary Fig. 6B). A database of alternative
splicing events was generated, based on the human RefSeq
database of transcripts (Release 66, August 2014). Splicing events
were characterized by a PSI (“percent spliced in”) score, and
changes compared to matched controls were determined by ΔPSI
values. In total, 42 transcriptome-wide splicing event changes
were observed under either treatment condition, with a ΔPSI of
> 0.4 (Fig. 3b, Supplementary Table 2), with NVS-SM1 affecting
36 transcripts and SMN-C3 only 13 (Supplementary Fig. 6C). In
addition, transcriptional proﬁling analysis demonstrated expres-
sion changes in 313 genes overall, considering both treatment
conditions (Fig. 3c; Supplementary Table 3), with 229 expression
changes for NVS-SM1 as opposed to 13 for SMN-C3 (Supple-
mentary Fig. 6D). These data demonstrate an unexpected higher
selectivity of SMN-C3 compared to NVS-SM1, suggesting an
additional mode of action than NVS-SM1’s previously described
U1 snRNA:5′ss interaction alone15.
This ﬁnding led us to investigate sequence homologies between
putative target genes of the SMN-C class compounds. As
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previously shown, only one gene besides SMN2, namely STRN3,
exhibited a strong magnitude of splicing change elicited by SMN-
C3 in SMA type 1 patient ﬁbroblasts. Apart from this, the other
signiﬁcant changes were strong splicing changes in a pseudogene
(PDXDC2P) or the downregulation of the entire PDXDC1 gene
that did not affect its splicing (see Fig. 2b in ref. 16). We therefore
searched for common sequence motifs around the alternatively
spliced exon 8 in STRN3, and identiﬁed an identical weak 5′ss and
a purine-rich region similar to the ESE2 motif in SMN2 (Fig. 4a).
We then tested the interaction of the splicing modiﬁers SMN-C5
(active), SMN-C7 (inactive), and NVS-SM1 with this ESE motif,
utilizing real-time label-free SPR technology. We monitored the
binding of these molecules to surface-immobilized SMN2 exon 7
and STRN3 exon 8 RNA fragments. SMN-C5 strongly bound to
ESE2, whereas NVS-SM1 showed no binding at all (Fig. 4b). We
extended our analysis to other distinct RNA cis elements within
exon 7 and intron 7 of SMN2, and observed strong binding only
to the full exon 7 (which includes ESE2) but little to no binding to
any other individual element (Fig. 4c). An analysis of SMN-C5
binding to the putative ESE in the STRN3 gene revealed even
stronger binding than to SMN2 ESE2 (Fig. 4d). NVS-SM1 did not
show detectable binding to any element analyzed (Fig. 4c, d).
SMN-C7 (Inactive), also bound to SMN2 ESE2 and the putative
ESE in the STRN3 gene although less potently (Supplementary
Fig. 7A, B), suggesting that binding to ESE2 is likely a speciﬁc
property of the SMN-C class compounds.
Finally, we investigated the binding of the splicing modiﬁers to
ESE2 using solution NMR spectroscopy. Chemical-shift pertur-
bations of the RNA resonances were the largest upon addition of
SMN-C5, and the weakest for NVS-SM1 (Supplementary Fig. 7C),
conﬁrming the direct binding of the SMN-C compounds to the
ESE2 RNA. Moreover, only the addition of SMN-C5 induced the
formation of broad imino signals in the proton 1D spectrum of
the complex ESE2:SMN-C5 (Supplementary Fig. 7D), indicating
that SMN-C5 may induce a conformational shift by binding to
ESE2. In conclusion, both SPR and NMR analyses conﬁrmed that
SMN-C class compounds bind to ESE2, in contrast to NVS-SM1.
Requirement of ESE2 and the 5′ss for SMN-C5 activity. Having
shown binding of SMN-C5 to single-stranded ESE2 RNA and to
the U1 snRNA:5′ss RNA duplex separately, we further investi-
gated if both the regions are important for SMN-C5 activity.
Therefore, we assessed SMN-C5 splicing activity via cell-based
splicing assays using SMN2 minigene constructs with ESE2
deletion and/or 5′ss mutation. SMN-C5 promoted exon 7 inclu-
sion in the construct with a deletion of the ESE2 region (ΔESE2,
Fig. 5a, c), although less efﬁciently (at higher compound con-
centrations) than in cells expressing the wild-type construct
(Fig. 5b). For the construct carrying a 5′ss mutation (G1C), there
was very little but detectable promotion of exon 7 inclusion with
SMN-C5 (Fig. 5d), suggesting that the 5′ss is the major site of
action. However, only in the double-mutant construct (ΔESE2 +
5′ss G1C), SMN-C5 was completely ineffective (Fig. 5a, bottom,
no quantiﬁcation possible). It should be noted, however, that
splicing of the double mutant is severely affected regardless of
treatment, consistent with the severity of the mutations created at
both the 5′ss and an important exonic splicing enhancer region.
In aggregate, these data suggest that both the 5′ss and ESE2 are
important sites of SMN-C5 activity, to promote exon 7 inclusion
in SMN2 transcripts.
Our investigations identiﬁed a small molecule that enhances 5′
ss recognition by targeting the major groove of the RNA complex.
We therefore sought to deﬁne protein components of the target
complex with ESE2, and used the ESE2 sequence as bait to
capture proteins from nuclear extracts of SMA type 1 patient
ﬁbroblasts, in the presence of either Active (SMN-C6) or Inactive
(SMN-C7) ligands. SMN-C6 but not SMN-C7 induced the
binding of 10 proteins with the ESE2 RNA (p-adj< 0.05, unique
peptides ≥ 2). Seven of these proteins are RNA-binding proteins
and two are part of U1 snRNP, namely the U1-A and U1-70K
proteins (based on String functional protein associate analysis,
Supplementary Fig. 9). An interaction between the ESE2 sequence
and U1 snRNP has not been, to the best of our knowledge,
previously described.
We also identiﬁed RBMX (also known as hnRNP G) protein as
one of the 10 proteins interacting with the SMN-C6–ESE2
complex. The hnRNP G protein binds in the ESE2 region of
SMN2 exon 7 and is known as a positive regulator of SMN2 exon
7 inclusion12. However, the mode of action of hnRNP G in SMN2
exon 7 splicing regulation is still not fully understood11, 12. When
tested in competitive binding assays, hnRNP G was displaced
from ESE2 by an excess of active SMN-C6 (Fig. 6a), whereas
Tra2-β1 and SRSF9 were not (Supplementary Fig. 10A, B),
suggesting a direct interaction of SMN-C6 at the RNA-interaction
site of hnRNP G. To conﬁrm this unexpected displacement of
hnRNP G at the ESE2 site by splicing modiﬁer binding,
we performed SPR-binding analyses of hnRNP G RRM to
ESE2 RNA immobilized on a Biacore sensor chip. Titration
experiments conﬁrmed the binding of hnRNP G to ESE2 RNA
(Supplementary Fig. 10C, D). When incubated in the presence
of micromolar concentrations of either SMN-C5, SMN-C7, or
NVS-SM1, we observed that only SMN-C5 but not SMN-C7 or
NVS-SM1 partially competed with the binding of hnRNP G RRM
to ESE2 (Fig. 6b, c), suggesting that binding of hnRNP G to
ESE2 seems to be partially inhibited in the presence of the Active
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changes signiﬁcant at the p= 0.001 level in any of the treatment conditions
(total of 313). Data in b and c represent mean values of 5 independent
replicates. **p< 0.01, ***p< 0.001 as estimated by Student’s t test
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compound. Furthermore, we observed NMR chemical-shift
perturbations towards the free-form state of the hnRNP G
protein when hnRNP G’s RRM bound to RNA was titrated with
SMN-C5 also at high concentrations (Supplementary Fig. 11B).
In contrast, we observed no difference in NMR spectra with the
Tra2-β1–RNA complex (Supplementary Fig. 11A), indicating that
SMN-C5 does not affect the interaction of Tra2-β1 with the ESE2
RNA. The absence of chemical-shift perturbation with SMN-C7
(Supplementary Fig. 11C) indicates that the effect on hnRNP G is
speciﬁc to the biological activity of the splicing modiﬁer,
suggesting that the SMN-C class compounds may bind at the
ESE2 region in SMN2 and displace hnRNP G from its ESE2-
binding site. The partial displacement of hnRNP G from the ESE2
region along with the pull-down of hnRNP G in chemical
proteomics experiments in the presence of SMN-C5 suggests a
direct interaction of the compound at the RRM-binding site of
hnRNP G; whether or not the partial displacement observed in
the in vitro systems translates into the more complete in vivo
context is beyond the scope of this study. There are several key
hypotheses that could explain the increasing selectivity of SMN-
C5, relative to other splicing modiﬁers, inﬂuenced by its
interaction at the ESE2 region, which we will address in the
discussion section.
Discussion
In Naryshkin et al. 201416, we introduced a compound class of
orally bioavailable splicing modiﬁers (SMN-C class) that promote
SMN2 exon 7 inclusion, and hypothesized that they are involved
in speciﬁc protein–RNA and/or RNA–RNA interactions. Using
cell-based in vitro splicing assays, SPR assays, solution-state
NMR, and chemical proteomics, we have now delineated that the
SMN-C class splicing modiﬁers stabilize an RNP complex that is
apparently unique to the transcripts of the SMN2 and STRN3
genes.
We have analyzed the modiﬁer’s effects on various cis-acting
elements and the corresponding trans-acting splicing factors
involved in SMN2 alternative splicing regulation. One way that
cis-acting sequences are known to inﬂuence exon 7 splicing is by
binding splicing activators that help to recruit spliceosomal
snRNPs28. As the 5′ss of exon 7 in SMN2 is a weak splice site
known for its suboptimal U1 snRNP binding, this may be a
limiting step in exon 7 inclusion efﬁciency8, 23, 29. In this context,
NVS-SM1, an SMN2 splicing modulator with a similar pharma-
cophore as the SMN-C class of compounds (Fig. 3a), was pro-
posed to act by increasing the interaction of U1 snRNP with the
5′ss15. Our analyses of solution-state NMR conﬁrmed that both
NVS-SM1 and the SMN-C class of splicing modiﬁers bind to the
5′ss of SMN2 exon 7, in agreement with the proposed model.
However, the precise site of action of SMN-C5 appears to be a few
nucleotides upstream in the 5′ss, compared to NVS-SM1. In
addition, we observed direct binding of SMN-C5 to the major
groove of the U1 snRNA:5′ss RNA duplex, close to the bulged B:
A3 (Fig. 2b), a region already known for its role in the low splicing
efﬁciency of exon 729. Thus, the two structurally related com-
pound classes share the mechanism of enhancing U1 snRNP
afﬁnity to the 5′ss, thereby making exon 7 inclusion more efﬁ-
cient. The inactive SMN-C7 bound to a slightly more down-
stream intronic region, demonstrating that the interaction with
the proximal region of the 5′ss seems to be important for the
compound′s biological activity.
By transcriptome-wide RNA-sequencing, we demonstrated
higher selectivity of SMN-C3 than NVS-SM1 on both transcript
splicing and expression levels. As the weak SMN2 exon 7 5′ss is
prevalent in many other genes15, inducing the U1 snRNA:5′ss
interaction alone would be insufﬁcient to explain the high
selectivity, suggesting an additional mechanism of action for the
SMN-C class compounds. As previously reported, the SMN-C
class of compounds modiﬁes splicing of a single additional gene,
SMN2, exon 7
STRN3, exon 8
ESE2 binding
SMN-C5
NVS-SM1
Buffer
125
100
150
Exon 7 Intron 7 Motifs
SMN-C5 10 μM
400
300
200
100
0
NVS-SM1 10 μM100
50
0
75
50
25
0
–5
0 0
–2
5 50 12
5
15
0
ES
E1
ES
E2
ES
E3
ES
E3
_T
LS
2
An
tis
en
se
 T
LS
2
Ex
on
7
IS
S-
N2
TS
TL
4/
6
I7
_c
TS
L7 GA GU
Time (s)
R
es
po
ns
e 
(R
U
)
%
 b
in
di
ng
10
07525
ESE2
ESE ?
Donor splice site
%
 b
in
di
ng
STRN3
“ESE”
a
b c d
Fig. 4 SMN-C5 binds to the SMN2 ESE2 and the STRN3 “ESE-like” structure. a Schematic illustration of the ESE2 region in the SMN2 exon 7, and the
putative ESE in the STRN3 exon 8 (indicated in pink). Note that the 5′ss of these two exons are identical (in blue). b Direct binding analysis on a SPR system
(Biacore 2000) to investigate the interaction between SMN-C5 or NVS-SM1 (10 µM each) and buffer control, to the immobilized ESE2 RNA in the SMN2
gene. Representative sensorgrams from triplicate experiments are depicted. c Quantitative assessment of binding of SMN-C5 and NVS-SM1 (10 µM each)
to distinct RNAs in the SMN2 gene (ESE1, ESE2, ESE3, ESE3_TLS2, antisense_TLS2, Exon 7, ISS-N2, I7_TSTL4/6, I7_c, I7_TSL7, “GA” motif, and “GU” motif)
immobilized on the SPR sensor. RNAs were captured via biotin on the streptavidin-coated sensor at surface densities in the range of 900–1200 RUs
(response units). The SPR signals monitored for small molecules are normalized to the molecular mass. 100% binding corresponds to the amplitude of SPR
signal monitored for binding of a small molecule to the RNA strand by full occupancy of one binding site (1:1 binding stoichiometry). d Binding to the STRN3
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STRN3, to a similar extent as SMN216. Upon examination of
common sequence motifs, we identiﬁed a purine-rich putative
ESE region similar to ESE2 in SMN2, and conﬁrmed the binding
of the SMN-C class of splicing modiﬁers to this region in STRN3,
as well as in SMN2. In addition, chemical proteomics experiments
demonstrated that the ESE2 sequence pulled down the U1 snRNP
proteins U1-A and U1-70K, as well as hnRNP G, in the presence
of the active SMN-C6. These results support the hypothesis that
the compounds can directly bind and potentially alter SMN2
RNA structures, thereby inﬂuencing their interactions with key
trans-acting splicing factors.
Moreover, the data strongly suggest the existence of a qua-
ternary RNP complex comprising the ESE RNA sequence, the 5′
ss, at least one SR protein, and U1 snRNP in the presence of the
splicing modiﬁer. It was therefore important to understand how
the SMN2 splicing modiﬁers affect binding of previously identi-
ﬁed trans-acting splicing factors to the SMN2 pre-mRNA. Tra2-
β1, a well characterized splicing activator, showed no change in
ESE2 binding in the presence of active SMN-C class compound,
whereas hnRNP G was partially displaced by SMN-C5. The
protein hnRNP G binds to part of the ESE2 region through
interactions with Tra2-β1, and acts additively with Tra2-β1 to
promote exon 7 inclusion5, 12, 14, 30, 31. As shown previously, exon
7 inclusion increases from ~20 to ~65% after overexpression of
hnRNP G alone12, 14, and hnRNP G and Tra2-β1 synergistically
enhance exon 7 inclusion to up to 80% when overexpressed
simultaneously14, 32.
The experimental displacement of hnRNP G in the presence of
an SMN-C class compound, as shown in the competitive binding
assays, highlights the interaction of SMN-C6 with hnRNP G and
ESE2—by directly altering the RNA-binding site or altering the
RNA structure to which hnRNP G normally binds. The mode of
action of hnRNP G in SMN2 exon 7 splicing regulation is still not
fully understood, and it is therefore difﬁcult to speculate on the
mode of action of the active molecule in this context. However, it
is plausible that hnRNP G may bind the ESE2 sequence around
the inhibitory stem loop (TSL1), thereby disrupting this structure
and improving the weak 3′ss region to further enhance exon
inclusion. The active molecule could then play the role of hnRNP
G with a higher efﬁciency by stabilizing the formation of an
alternative RNA base-pairing that further reduces the inhibitory
effects of the TSL1. Another attractive hypothesis would be that
the molecule simply reorganizes the positioning of hnRNP G on
the exon 7 and reinforces its activity as a splicing activator. In
addition, binding of the active compound to the hnRNP G-
binding site can result in interaction with other splicing enhan-
cers, which we demonstrated by the chemical proteomics and
pull-down studies, showing that Active SMN-C6 binding to ESE2
recruit proteins involved in the larger spliceosomal complex.
Finally, we hypothesize that possibly more than one small
molecule interacts simultaneously with the ESE and the 5′ splice
site duplex (Fig. 7). Rigorously testing these putative mechanisms
warrants further investigation.
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Fig. 5 Requirement of both 5′ss and ESE2 mutation/deletion for full abolishment of SMN-C5 activity. a Cell-based splicing assay of SMN2 minigene
constructs in HEK293 cells treated with increasing concentrations of SMN-C5 (0.01–10 µM) in wild-type constructs and in constructs harboring a 5′ss
mutation (G1C), a deletion of the ESE2 region (ΔESE2) or both 5′ss G1C and ΔESE2. In the double-mutant construct (ΔESE2 + 5′ss G1C), the SMN-C5
effect was completely abolished. Full blots shown in Supplementary Fig. 8. b, c, d Quantitative assessment of the data by RT-qPCR. b Wild-type (WT), c
ESE2 deletion, c 5′ss G1C point mutation construct. Double mutation of 5′ss and ESE2 did not yield quantiﬁable results. Data represent means± SEM of
three independent transfections
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In summary, our data show that in addition to the
U1 snRNP:5′ss interaction in SMN2 exon 7, U1 snRNP can also
interact directly or indirectly with the ESE2 motif, and these
interactions can be modulated by small molecules in a coordi-
nated fashion thus providing speciﬁcity towards regulation of
SMN2 alternative splicing (Fig. 7). Our data suggest a potential
formation of an RNA tertiary structure with the 5′ss, explaining
the high selectivity of the SMN-C class of compounds, with
splicing of only two pre-mRNAs being affected at physiological
concentrations and further substantiated by the similarity of
STRN3 and SMN2 (Fig. 4a).
Our report suggests that a splicing deﬁcit of an individual gene
can be selectively targeted through speciﬁc small molecule
interactions with RNA:protein complexes. As further ﬁndings
highlight mis-splicing to be the cause of many disease-causing
mutations3, 33, the work presented here has the potential to have
widespread implications in the research and development of such
RNA-targeting therapies.
Methods
Selection of chemical class of splicing modiﬁers. Both compounds SMN-C3 and
SMN-C5 belong to the same chemical class. SMN-C5 was prepared on the same
basis as C3 and shares the exact same pharmacophore. The two compounds SMN-
C3 and SMN-C5 have a perfect overlay of every critical atom being exactly in the
same position, with exactly the same fully planar spacer. These similarities provide
the similar selectivity and speciﬁcity. The active ligand out of SMN-C5 needed for
the chemical proteomics pull-down experiments required the generation of SMN-
C6L, which was modiﬁed at the end where biological activity was minimally
affected.
Preparation of chemical proteomics ligands. The SMN splicing modiﬁers SMN-
C6 and SMN-C6L and their negative controls SMN-C7 and SMN-C7L were syn-
thesized from the published corresponding N-H piperazine derivate, 2-(8-ﬂuoro-2-
methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-
4-one34 (CAS: 1449592-34-0) by alkylation with Boc-protected aminopropyl-
bromide and subsequent deprotection yielded SMN-C6. This compound in turn
was acylated with pentanoyl chloride to yield SMN-C6L. SMN-C7 was prepared
from the same starting material, the NH-piperazine, through coupling of 3-(tert-
butoxycarbonylamino)propanoic acid with HBTU and subsequent deprotection
and SMN-C7L through coupling with 3-pentanamidopropanoic acid. The synthesis
details are provided as follows:
For preparation of 7-(4-(3-aminopropyl)piperazin-1-yl)-2-(8-ﬂuoro-2-
methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
trihydrochloride (SMN-C6), in a ﬁrst step, a suspension of 2-(8-ﬂuoro-2-
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Fig. 6 Displacement of hnRNP G from SMN2 exon 7 ESE2 by small molecule splicing modiﬁers. a Protein abundance (log2) of hnRNP G after afﬁnity
enrichment with the SMN2 ESE2 RNA sequence as bait, in the presence of increasing concentrations of Active (SMN-C6) or Inactive (SMN-C7) ligand. b
SPR-binding curves monitored for hnRNP G RRM over ESE2 surface at a single hnRNP G concentration of 1.5 µM (green) and competition of hnRNP G-ESE
2 interaction by SMN-C5 (blue), SMN-C7 (red), or NVS-SM1 (black). ESE2 was immobilized on a streptavidin surface (CAP sensor) to a density of ~25 RU.
Small molecules were titrated from 3.13 to 50 µM at constant hnRNP G concentration (1.5 µM). c Quantitative assessment of normalized SPR signals of
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Fig. 7Working model of the proposed molecular interactions of the SMN-C
type SMN2 splicing modiﬁers. SMN-C type compounds bind to two sites at
the SMN2 exon 7, namely ESE2 and 5′ss when U1 snRNA is bound.
Whereas interaction with the 5′ss drives promotion of exon 7 inclusion in
the splicing process, binding to ESE2 results in hnRNP G dislocation and
allows the U1 snRNP complex to bind to ESE2. Both binding processes in
combination provide high selectivity to the SMN2 and STRN3 pre-mRNAs
over other genes
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methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-
4-one (CAS: 1449592-34-0, 119 mg, 314 µmol), tert-butyl 3-
bromopropylcarbamate (85.8 mg, 346 µmol) and potassium carbonate (52.2 mg,
377 µmol) in dimethylacetamide (3.2 ml) was stirred over night at 60°C under
stirring. The reaction was diluted with water, extracted twice with
dichloromethane. The combined organic layer was washed once with saturated
aqueous sodium chloride solution, dried over sodium sulfate, ﬁltered and the
solvent was evaporated under reduced pressure. The residue was puriﬁed by
column chromatography on silica gel (CH2Cl2:MeOH 9:1) to yield the title
compound as a yellow solid (95 mg, 56.4 %). MS ISN (m/e): 580.5 (100) [(M +
HCOOH-H)-] to yield tert-butyl 3-(4-(2-(8-ﬂuoro-2-methylimidazo[1,2-a]pyridin-
6-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl)piperazin-1-yl)propylcarbamate. In a
second step, to a solution of tert-butyl 3-(4-(2-(8-ﬂuoro-2-methylimidazo[1,2-a]
pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl)piperazin-1-yl)
propylcarbamate (95 mg, 177 µmol) in dichloromethane (1.77 ml) was added
hydrochloric acid 4 M in dioxane (222 µl, 887 µmol). The reaction was stirred at
room temperature overnight. The reaction was diluted with diethyl ether and the
precipitate was ﬁltered off and dried to yield the title compound as a yellow powder
(83 mg, 85.9 %). MS ISP (m/e): 436.3 (5) [(M +H) + ], 218.7 (100) [(M/2 + H) + ]
to yield 7-(4-(3-aminopropyl)piperazin-1-yl)-2-(8-ﬂuoro-2-methylimidazo[1,2-a]
pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one trihydrochloride (SMN-C6).
A suspension of 7-(4-(3-aminopropyl)piperazin-1-yl)-2-(8-ﬂuoro-2-
methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one (10 mg, 23.0
µmol) and triethylamine (6.97 mg, 9.55 µl, 68.9 µmol) in dimethylacetamide
(0.3 ml) was added pentanoyl chloride (3.32 mg, 3.27 µl, 27.6 µmol) and stirred at
room temperature for 1 h. The light yellow suspension was poured into 5 ml of
water and extracted twice with dichloromethane. The organic layer was washed
with saturated aqueous sodium chloride solution, dried over sodium sulfate, ﬁltered
and concentrated in vacuo to yield the title compound as a light yellow oil (4 mg,
33.5 %). MS ISP (m/e): 260.8 [(M/2 + H) + ] to further yield N-(3-(4-(2-(8-ﬂuoro-
2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl)
piperazin-1-yl)propyl)pentanamide (SMN-C6L).
To prepare 7-(4-(3-aminopropanoyl)piperazin-1-yl)-2-(8-ﬂuoro-2-
methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
dihydrochloride (SMN-C7), in a ﬁrst step tert-butyl 3-(4-(2-(8-ﬂuoro-2-
methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl)
piperazin-1-yl)-3-oxopropylcarbamate was generated. To a suspension of 2-(8-
ﬂuoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]
pyrimidin-4-one (CAS: 1449592-34-0, 130.6 mg, 345 µmol) und 3-(tert-
butoxycarbonylamino)propanoic acid (71.8 mg, 380 µmol) in DMA (1.72 ml) was
added under stirring and an athmosphere of nitrogen triethylamine (105 mg, 144
µl, 1.04 mmol) and HBTU (200 mg, 518 µmol). The reaction was stirred over night
at room temperature. Water was added and the reaction was extracted three times
with methylene chloride. The combined organic layer was washed once with water,
dried over sodium sulfate, ﬁltered and the solvent was evaporated under reduced
pressure. The residue was puriﬁed by column chromatography on silica gel
(CH2Cl2 to CH2Cl2:MeOH 9:1) to yield the title compound as a yellow
solid (152 mg, 80.1 %). MS ISP (m/e): 550.4 (100) [(M +H) + ], 225.7 (37) [(M/2 +
H) + ]. In a second step, to a solution of tert-butyl 3-(4-(2-(8-ﬂuoro-2-
methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl)
piperazin-1-yl)-3-oxopropylcarbamate (152 mg, 277 µmol) in dichloromethane
(2.8 ml) was added under stirring a solution of 4 M hydrogen chloride solution in
dioxane (346 µl, 1.38 mmol). The reaction was stirred over night at room
temperature, diluted with diethyl ether and the precipitate was ﬁltered off, washed
with diethyl ether and dried in high vacuum at 45 °C to obtain the title compound
as a yellow powder (141.4 mg, 97.9 %). MS ISP (m/e): 450.2 (5) [(M +H) + ], 225.7
(100) [(M/2 + H) + ] to yield to prepare 7-(4-(3-aminopropanoyl)piperazin-1-yl)-
2-(8-ﬂuoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-
one dihydrochloride (SMN-C7). Further, a yellow solution of 2-(8-ﬂuoro-2-
methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-
4-one (10 mg, 26.4 µmol), 3-pentanamidopropanoic acid (4.58 mg, 26.4 µmol),
triethylamine (13.4 mg, 18.3 µl, 132 µmol), and 2-(1H-benzo[d][1–3]triazol-1-yl)-
1,1,3,3-tetramethylisouronium hexaﬂuorophosphate(V) (13.0 mg, 34.4 µmol) in
dimethylacetamide (0.3 ml) was stirred at 60 °C for 5 h. The reaction mixture was
evaporated, and the resulting solid was puriﬁed by ﬂash chromatography (silica gel,
0 to 10% MeOH in dichloromethane) to yield the title compound as a light yellow
solid (7 mg, 49.6 %). MS ISP (m/e): 534.5 (100) [(M +H) + ] to yield N-(3-(4-(2-(8-
ﬂuoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-
yl)piperazin-1-yl)-3-oxopropyl)pentanamide (SMN-C7L).
Chemical proteomics of splicing inducers. Coupling of the compound derivatives
to the NHS-activated beads (GE Healthcare) was performed by incubation of 1
µmol of compound with 1 ml of bead solution. After binding overnight at room
temperature in DMSO and 1.5% triethylamine, any remaining reactive groups were
blocked with 33% (ﬁnal volume) ethanolamine for 24 h at room temperature.
Subsequent washing steps were performed with DMSO. Binding efﬁciency was
estimated by comparing the optical densities of the compound solutions before and
after coupling at the maximal absorbance wavelength 292 nm35.
Heavy and light SILAC labeled SMA type 1 ﬁbroblasts were lysed in 50 mM
HEPES pH 7.5 buffer containing 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 0.5%
NP-40, protease inhibitors (Roche), sonicated using a Branson Digital Soniﬁer on
ice. Samples were then cleared by centrifugation at 12,000 × g for 10 min at 4 °C.
Heavy or light supernatants were loaded in quintuples onto Sepharose® beads
immobilized with the active or inactive derivative for 1 h at 4 °C under rotation.
Beads were washed three times with lysis buffer, treated with SDS-PAGE sample
buffer for 5 min at 85 °C, and identical volume of both elutions (active and inactive
beads) were combined. For the experiment using RNAse, an additional step was
added before elution, using RNAse A (Roche) at 1.5 U μl−1 for 20 min at room
temperature. Eluates were separated on 4–20% Tris-Glycine SDS-PAGE. After
protein ﬁxation in 40% ethanol and 10% acetic acid, gels were stained overnight
with Coomassie Brilliant blue. Each gel lane was cut into seven slices between the
20 and 150 kDa region, in-gel digested as described above, and stored at −20 °C
prior to analysis. Samples were re-constituted in 2% acetonitrile/5% formic acid
and analyzed by liquid chromatography–mass spectrometry (LC–MS) using an
Easy-nLC coupled to an LTQ Orbitrap Velos Pro (Thermo Fisher Scientiﬁc)
equipped with a Digital PicoView 550 source (New Objective, Woburn, MA) and
an active background ion reduction device (ABIRD, ESI Source Solutions, Woburn,
MA). Peptides were loaded onto an Aqua C18 (Phenomenex, Torrance, CA)
trapping column (packed in-house, 10 mm length × 100 μm inner diameter, 5 μm
particle size) and separated on a Reprosil-Pur C18-AQ (Dr. Maisch GmbH,
Ammerbuch, Germany) analytical column (200 mm length × 75 μm inner
diameter, 3 μm particle size, 120 Å) using the following gradient at 250 nl per min:
0–2% B in 2 min, 2–35% B in 46 min, 35–80% in 2 min, and 80% B for 10 min
(buffer A: 0.6% acetic acid; buffer B: 0.6% acetic acid/acetonitrile). The eluent was
electrosprayed via uncoated SilicaTip emitters by applying 1.7-2-0 kV spray voltage
via a liquid junction. The mass spectrometer was operated in the data dependent
mode to automatically switch between MS and MS/MS. Survey full scan MS spectra
were acquired from m/z 350 to 1700 in the Orbitrap with a resolution of R = 60,000
(at m/z 400) after accumulation to a target value of 1 × 106 in the linear ion trap for
a maximum time of 500 ms. The detected ions were recalibrated on-the-ﬂy using
the ambient air polysiloxane at m/z 445.120024 as lock-mass (51). The 10 most
intense ions with a charge state> 1 + and a threshold above 1000 were selected for
collision induced dissociation (CID) in the linear ion trap. Ions were accumulated
to a target value of 10,000 using the predictive ion trap ﬁll time mode, isolated with
a width of 2 amu, CID performed at a normalized collision energy of 35% with an
activation Q of 0.25 for 10 ms and wideband activation mode enabled. Fragmented
ions with a m/z width of ±10 ppm width were placed on an exclusion list for 30 s
and a maximal size of 500. Raw ﬁles were processed using Mascot Distiller 2.5.1.0
(Matrix Science) and peak lists were searched against the human UniProt/
SwissProt database (December 2013 release, 20,274 sequences) using Mascot
server. Trypsin/P was used as an enzyme, allowing for a maximum of one
miscleavage, 20 ppm and 0.5 Da as precursor and fragment mass tolerances,
respectively. Carbamidomethylated cysteine was selected as ﬁxed, while oxidized
methionine, was set as variable modiﬁcations. SILAC variable modiﬁcations Lys8
and Arg10 (heavy) were set in the SILAC quantiﬁcation method. Individual peptide
to spectrum matches were ﬁltered using maximum expect p-value corresponding to
a false discovery rate of ≤1% as determined by enabling the decoy database search.
SILAC peptide quantitation and ratio generation was performed with Mascot
Distiller using the following settings: precursor ion protocol, Simpson’s rule as
integration method, minimal Rho correlation of 0.7, and an XIC threshold of 0.1.
Ratios median was calculated for protein with a minimum of two quantiﬁed
peptides. Peptide level protein quantitation reports were generated in html format
for further processing. HTML reports were loaded into R 3.1.0 for statistical
analysis, and only protein hits with at least two peptides, a Mascot Score> 31,
found in at least 7 out of 10 samples and were used in subsequent analysis. The SDS
band where a given protein was identiﬁed with highest abundance was kept, and
protein entries in the other bands were discarded. Ratios of reversed peptides ratios
were reversed, and all ratios were log2-transformed. One-sided t tests were
performed, with the null hypothesis that the mean of the log-transformed ratios of
a given protein equals 0. The corresponding alternative hypothesis states that the
original, not-transformed ratios H:L (after H:L reversion, where appropriate) are
signiﬁcantly greater than 1:1. The p-values of the one-sided t-test were adjusted for
multiple testing following Benjamini and Hochberg36. Proteins were considered as
signiﬁcantly and relevantly enriched if both the adjusted p-value ≤ 5 % and the
ratio between groups> 1:1.5 were found.
From pull-down experiments with active and inactive compound, proteins were
selected that showed at least 1.5 fold enrichment for the active compound, with an
adjusted p-value of 0.05 or less. This produced a list of 430 proteins. Using the
GO_SLIM collection of gene ontology annotations (http://ceur-ws.org/Vol-1546/
paper_44.pdf), these proteins were found to be enriched for 8 categories based on
Fisher’s exact test and using a p-value cutoff of 0.001. Each of them is characterized
by the negative logarithm of the enrichment p-value on the x axis of Supplementary
Fig. 4A; the full is given in Supplementary Table 3. The category “translation”
scored best, but is not related to the compound’s mode of action. Reasoning that
proteins involved in the translational machinery would be associated through their
interactions with RNA, we produced a second list of 339 proteins by manually
removing all ribosomal proteins from the original list. Repeating the enrichment
analysis, we obtained drastically smaller or at best very similar enrichment p-values
(y axis in Supplementary Fig. 4A), with the exception of the “RNA splicing”
category, which scored substantially better. We conclude that this category is the
strongest hit in our search that is independent of the (inevitable) presence of
ribosomal proteins in our data set.
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RNA pulldowns with proteomics. 100 pmol of 5 biotinylated ESE2 sequence (5′-
AAAAAGAAGGAAGG-3′) was bound to 50 μl of streptavidin magnetic beads
according to the manufacturer’s instructions (PierceTM Magnetic RNA–protein
pull-down kit; Thermo Scientiﬁc; Rockford, USA). SMA type 1 human ﬁbroblasts
pellets were resuspended in 10 mM HEPES pH7.8, 1 mM MgCl2, 10 mM KCl,
protease inhibitors (cOmplete™ Protease Inhibitor Cocktail EDTA free Roche) and
homogenized with a potter. Lysates were centrifuged at 500 × g for 10 min at 4 °C.
Pelleted nuclei were resuspended in 50 mM HEPES pH 7.3 buffer containing
150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 0.5% NP-40, protease inhibitors, RNase
inhibitors (Protector, Roche), and sonicated using a Q125 sonicator (Qsonica).
Samples were then cleared by centrifugation at 300 × g for 10 min at 4 °C and the
supernatant was incubated for 1 h 30 min at 4°C with bead-immobilized
ESE2 sequence as bait. For competition experiments, lysates were pre-incubated for
1 h 30 min with increasing amounts of SMN-C6 or SMN-C7 (0; 0.5; 1; 5 and 10 μM
ﬁnal concentration) in triplicates. After washing 3 times in lysis buffer, proteins
were eluted in reducing SDS-PAGE sample buffer for 5 min at 85°C. Eluates were
separated on 4–20% Tris-Glycine SDS-PAGE and stained with Coomassie Brilliant
blue. Gel lanes were cut in ﬁve bands spanning from 20 to 120 kDa. For protein in-
gel digestion, an adapted protocol from Shevchenko et al.37 was used. Proteins were
reduced with 50 mM dithiothreitol for 45 min at 56 °C, alkylated with 55 mM
iodoacetamide for 1 h in the dark, and digested with trypsin (Promega) overnight
at room temperature. Peptides were extracted twice with 1:2 (v/v) acetonitrile/
25 mM ammonium bicarbonate, and 1:2 (v/v) acetonitrile/5% formic acid,
respectively, for 15 min at 37 °C. Dried samples were re-constituted in 2% acet-
onitrile/5% formic acid and run in quintuples by LC–MS, using an EASY-nLC 1000
ultrahigh pressure liquid chromatography) coupled to an Orbitrap Fusion Mass
spectrometer (Thermo Fisher Scientiﬁc, Bremen, Germany). Samples were con-
centrated on an Acclaim PepMap C18 trapping column (100 μm× 20 mm, 5 μm
particle size). Peptides were separated on an Acclaim PepMap C18 EASY-spray
column (75 μm× 500 mm, 2 μm particle size) using the following gradient at 300 nl
per min: 7–50% B in 45 min, 50–80% B in 2 min, 80% B for 13 min, corresponding
to a total time of 60 min (buffer A: 0.1% formic acid; buffer B: 0.1% formic acid/
acetonitrile). Data were on-the-ﬂy recalibrated using ambient air hex-
acyclodimethylsiloxane at m/z 445.1200238. The ten most intense precursor ions,
with charge states between 2 and 6, a minimum intensity of 5E3, were mono-
isotopically selected for higher-energy collisional dissociation, using a quadrupole
isolation of m/z 0.7, automatic gain control target of 1E4, maximum IT of 35 ms,
collision energy of 30%, and ion trap readout with rapid scan rate. Only a single
charge state per precursor was selected for MS2. Interrogated precursor ions were
dynamically excluded for 75 s using a ±10 ppm mass tolerance. Raw ﬁles were
processed using Progenesis QI 2.1 (Nonlinear Dynamics; Newcastle, UK) and
Mascot Server 2.5.1 (Matrix Science, London, UK) together with the UniProt/
SwissProt human protein database (08.2015 release, 20,204 entries without splice
variants) using trypsin/P as an enzyme, a maximum of two missed cleavage sites,
10 ppm, and 0.5 Da as the precursor, and fragment ion tolerances, respectively.
Carbamidomethylated cysteines (+57.02146 Da) were set as static while oxidized
methionines (+15.99492 Da) were set as dynamic modiﬁcations. For statistical
analysis of the raw data and in order to detect proteins displaced with increasing
free SMN-C6 and SMN-C7 concentration, the concepts of contrast tests39, 40
combined with a moderated linear model41, 42 were applied35. Monotonic contrasts
were used to compare the protein abundance values above and below each con-
centration point, and the maximum of the resulting series of t-statistic values was
determined for each protein quantitation group. To obtain the p-values, the con-
centration labels were permuted 1000 times based on the step-down minP
algorithm43, 44 modiﬁed for one-sided tests, and adjusted for multiple testing36.
Proteins with adjusted p-values below 5% were considered as speciﬁc binders.
Computations were performed in R (version 3.3.2; http://www.r-project.org/).
PCR after compound pull-downs. After incubation with cell lysate and washing of
Sepharose beads immobilized with the active or inactive SMN-C5 analogs, RNA
was released from the beads by adding QIAzol reagent and isolated using the
miRNeasy Mini kit combined with DNase treatment on a solid support (Qiagen
Inc., USA). Equal volumes of both elutions (active and inactive beads) were used
for cDNA synthesis in separate reactions at 50 °C using the Transcriptor ﬁrst
strand cDNA synthesis kit with random hexamer and oligo-dT primer (Roche).
Real-time quantitative PCR was performed on a Roche LightCycler LC480
instrument using a ﬁxed volume of cDNA as input in a 20 µl mixture containing
LightCycler 480 Probes Master (Roche), 0.4 µM forward and reverse primers, and
0.2 µM FAM labeled hydrolysis probe. The temperature cycle consisted of pre-
incubation at 95 °C for 10 min and 50 cycles of ampliﬁcation (95 °C for 10 s, 60 °C
for 30 s, 72 °C for 2 s). Fold enrichment of active above inactive derivative was
calculated with the 2-ΔΔCt method. The primer and probes used for RT-qPCR are
described in Supplementary Table 4.
RT-qPCR analysis of SMN2 full length and Δ7 mRNAs. SMA type 1 patient cells
were plated at 7000 cells per well in 200 μl Dulbecco’s modiﬁed Eagle’s medium
(DMEM) with GlutaMAX and 10% fetal bovine serum (FBS) (Life Technologies,
Inc.) in 96-well plates. After the cells were adhering, the treatment started with the
SMN-C3 at different concentrations (0.5% DMSO) and with different inhibitors
(Supplementary Table 4) in triplicates for 6 h in a cell culture incubator (37°C, 5%
CO2, 100% relative humidity). After removal of the supernatant, cells were lysed in
Cells-To-Ct lysis buffer (Life Technologies, Inc.) according to the manufacturer’s
recommendations.
The mRNA levels of SMN2 FL, SMN2 Δ7, STRN3 FL, STRN3 Δ8/9, and
GAPDH were quantiﬁed using Taqman-based RT-qPCR and SMN2-speciﬁc
primers and probes in Supplementary Table 5 (purchased from Life Technologies,
Inc. or Microsynth. Inc.). The SMN2 forward and reverse primers were each used
at a ﬁnal concentration of 0.4 μM. The SMN2 probe was used at a ﬁnal
concentration of 0.15 μM. GAPDH primers were used at ﬁnal concentrations of 0.1
μM and the probe at 0.075 μM. RT-qPCR was carried out at the following
temperatures for indicated times: Step 1: 48 °C (15 min); Step 2: 95 °C (10 min);
Step 3: 95 °C (15 sec); Step 4: 60 °C (1 min); Steps 3 and 4 were repeated for 40
cycles. The Ct values for each mRNA were converted to mRNA abundance using
actual PCR efﬁciencies. SMN2 FL and Δ7 mRNAs were normalized to GAPDH and
DMSO controls and plotted as fold change compared to DMSO treatment.
Bioinformatic analysis of RNA-sequencing data. To estimate gene expression
levels, paired-end RNASeq reads were mapped onto the human genome (hg19) by
using the short read aligner GSNAP45, 46 and RefSeq transcript annotations.
Mapped reads for all transcript variants of a gene (counts) were combined into a
single value, normalized and denoted as rpkms (number of mapped reads per
kilobase transcript per million sequenced reads)47. Differentially expressed genes
were determined by using the DESeq48 package in R/Bioconductor with number of
mapped reads per gene as input. For the splice-site analysis (see below), paired-end
RNASeq reads were mapped onto RefSeq human transcripts using the alignment
software GSNAP with default parameters and the option “sam-multiple-primaries”
in order to account for reads that map multiple times to different splice variants.
The number of reads spanning splice sites was determined by applying the sam-
tools mpileup software49 with default parameters for each transcript. Reads were
excluded from the analysis if their start or end coordinate mapped exactly onto the
splice-site.
RNAseq alternative splicing analysis. The sequencing reads generated do not
allow unambiguous identiﬁcation of full-length transcript variants. Therefore, we
generated a database of local alternative splicing events based on the human RefSeq
database of transcripts (Release 66, August 2014). Such local splicing events we
classiﬁed into the following categories:
CASSETTE—inclusion or skipping of a single exon
INTERNAL3—use of an alternative 3′ acceptor splice site, leading to a length
polymorphism
INTERNAL5—use of an alternative 5′ donor splice site, leading to a length
polymorphism
LCASSETTE—joint inclusion or skipping of two exons
MUT_EXCLU—mutually exclusive usage of one out of two exons
XCASSETTE—joint inclusion or skipping of three or more exons. For each
local splicing event, we distinguish between two alternatives, e.g., including or
skipping the exon in the case of a CASSETTE event, and we collect all the
sequencing reads that are unique for either alternative; for the CASSETTE case,
these are reads covering the different splice junctions or mapping fully to the
alternative exon. We normalize the obtained read counts for either alternative by
the length of the unique sequence stretch (which is typically longer for the exon
inclusion alternative) to obtain normalized counts c1 and c2 for the two
alternatives, respectively.
Splicing events are then characterized by a PSI (“percent spliced in”) score PSI
= c1/(c1 + c2), which ranges from 0 to 1. Changes were determined by ΔPSI values
(relative to matched controls). 57,634 local splicing events were represented by
normalized read densities of at least 0.003 for at least one variant. For all of these,
we calculated ΔPSI values. In total, 42 transcriptome-wide splicing events were
observed with a ΔPSI of >0.4 for at least one of the treatment conditions.
SPR direct binding assay. All SPR experiments were performed on the Biacore®
3000 and 2000 (GE Healthcare, Uppsala, Sweden) instruments at 25 °C. Running
buffer composed of 10 mM HEPES, 150 mM NaCl 0.05% P20 (w/v), 35 mM EDTA,
0.1% (v/v) DMSO, pH 7.4 and ﬂow rate of 30 µl min−1 were used by direct binding
assays with small molecule compounds. Running buffer composed of 20 mM
NaH2PO4, 150 mM NaCl, pH 5.5 and ﬂow rate of 50 µl min−1 were used in binding
assay with hnRNP G and ESE2, and further competition assay with small molecule
compounds. Running buffers were prepared freshly, ﬁltered with Express™Plus
steritop ﬁlters with 0.22 µm cut off (Millipore, Billerica, MA, USA) and degassed
prior the SPR analysis. 5′- biotinylated RNA Sequences were obtained from
Microsynth AG (Balgach) and were dissolved in RNase-free water to concentra-
tions of 100 µM. The RNA aliquots were stored at −20 °C and used only once.
Biotinylated RNAs were captured via biotin on streptavidin pre-coated SA sensors
(GE Healthcare BR-1000-32) or CAP sensor (GE Healthcare, 28-9202-33). SA
streptavidin sensor was conditioned ﬁrst with 3 consecutive 1 min injections of
high salt solution in sodium hydroxide (50 mM NaOH, 1M NaCl). Next, RNAs
were diluted in running buffer 1000 times from stock solution (100 µM) and
applied over streptavidin sensor surface to achieve immobilization levels of RNA of
about 1000 RU. Finally, free biotin solution (10 µM in running buffer) was injected
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once (1 × 1 min) over sensor surface to block remaining binding sites in strepta-
vidin. CAP sensor was used to monitor hnRNP G RRM peptide - ESE2 interactions
and in competition assays. First, hybridization of DNA-streptavidin conjugate on
the pre-coated complementary ssDNA was performed according standard proto-
col. Next, biotinylated ESE2 was immobilized to relatively low level of ~20 RUs.
Finally, saturation of free binding sites in streptavidin was performed with a biotin
solution similarly as on SA sensor. After titration of hnRNP G over ESE2 surface
the entire DNA-streptavidin-ESE2-hnRNP G complex was washed away from the
sensor using regeneration solution of 6 M guanidine hydrochloride in 0.25M
NaOH and further the new hybridization of DNA-streptavidin conjugate on the
CAP sensor, immobilization of biotinylated ESE2 and ﬁnally hnRNP G titration
experiment were performed.
For binding experiments of small molecule ligands to various RNA regions,
SMN2 splicing modiﬁer compounds were obtained from Roche (Basel,
Switzerland) as powders, dissolved in 100% DMSO to a stock concentration of 5 or
10 mM. For the measurements, the samples were heated 5 min to 65 °C and ﬁnally
cooled to the room temperature. Binding experiments were performed under the
same conditions as immobilization of RNAs. Binding of small molecule ligands to
various RNA regions (Supplementary Table 6) was analyzed at a single
concentration (10 µM) in ﬁve replicates.
To assess binding of hnRNP G RRM peptide to ESE2 and competition by small
molecules, hnRNP G RRM was diluted in the running buffer (described above) and
titrated (0.094–1.5 µM, dilution factor of 2) over ESE2 surface in quadruplicates.
For the competition experiments hnRNP G RRM at a single concentration (1.5
µM) was pre-incubated with a concentration range of small molecule (3.13–50 µM,
dilution factor of 2) and applied over the ESE2 surface. Five consecutive injections
of hnRNP G at 1.5 µM were performed as a control experiment.
SPR data analysis was performed using BiaEvaluation Software (version 4.1)
and GraphPadPrism (version 6.04). All monitored resonance signals were single
referenced, i.e., signals monitored on the binding active channel were subtracted
with signals from a reference channel (sensor surface not modiﬁed with any RNA,
but saturated with free biotin). To compare binding of different molecules on
various RNA regions, the resonance signals were normalized to molecular mass
and RNA surface densities, and expressed as % binding.
Cell culture and transfection. HEK293 cells (ATCC) were cultured in DMEM
(4.5 g per l glucose, L-glutamine and sodium pyruvate, Corning 10-013-CV) + 10%
FBS. For transfection with plasmid DNA, the cells were plated in 24-well plates the
day prior to transfection at 5 × 105 cells per well. Transfection of 0.25 µg plasmid
DNA per well was carried out using Lipofectamine 2000 (Life Technologies, 11668-
019) according to the manufacturer’s instructions. 24 h post-transfection, cells were
treated with 0–10 µM of splicing modiﬁer for 24 h. Cells were lysed using 300 µl
TRIzol reagent (Life Technologies, 15596018) per well.
RNA extraction. To each 300 µl TRIzol sample, 80 µl chloroform were added and
mixed vigorously. The samples were centrifuged 15 min to separate the phases. The
upper aqueous phase was transferred to a new tube and mixed with one volume of
isopropanol. After incubation for 10 min at room temperature, the RNA was
pelleted by centrifugation for 15 min at 4 °C. The pellet was washed with 75%
ethanol and air-dried for 5–10 min at room temperature. After resuspension in 20
µl RNase-free water, 2.2 µl 10× RQI DNase buffer (Promega, M198A) and 1 µl RQI
DNase (Promega, M610A) were added and the samples were incubated at 37 °C
for> 30 min. After addition of 2.4 µl RQI stop solution (Promega, M199A) the
samples were incubated for 2 min at room temperature, spun down for 2 min, and
transferred to a fresh tube. Samples were stored at −20 °C short term.
cDNA synthesis. A total of 400 ng RNA were mixed with 1 µl oligo-dT primer
(18-mer, 0.5 µg µl−1) and diluted with RNase-free water 5 µl total volume. The
samples were incubated at 75 °C for 5 min and put on ice. In a separate tube, 6.6 µl
nuclease-free water were mixed with 4 µl ImProm-II 5× reaction buffer (Promega,
M289C), 2.4 µl MgCl2 (25 mM), 1 µl dNTP mix (10 mM), and 1 µl ImProm-II
reverse transcriptase (Promega, M314C). This solution was added to the RNA/
primer sample and the reaction mix was incubated 5 min at room temperature, 1 h
at 42 °C, and 15 min at 70 °C. The samples were centrifuged for 2 min and
transferred to a fresh tube. Samples were stored at −20 °C.
Radioactive PCR and gel analysis. Three µl of DNA loading dye were added to
each reaction, then 3 µl were loaded on a 6% acrylamide gel (2 ml TBE 10×, 4 ml
Bis/Tris Acrylamide solution 30%, 14 ml water, 180 µl APS 10%, 18 µl TEMED).
Gel electrophoresis was carried out in 1× TBE buffer at 400 V for 1.5 h. The gel was
dried for 25 min at 88 °C under vacuum, and analyzed by autoradiography.
In vitro transcription. To prepare the template for the in vitro transcription, the
pCI-neo plasmid containing a T7 promoter upstream of the gene of interest was
linearized using SalI. After gel puriﬁcation, the in vitro transcription reaction mix
was prepared as follows: 9.4 µl of this mix were combined with 2.1 µl of the line-
arized DNA template and 1 µl T7 RNA polymerase (1.36 mgml−1) in in vitro
transcription buffer (Supplementary Table 7). The reactions were incubated for
90 min at 37 °C. After incubation, 10 µl of loading dye (100% formamide +
bromophenol blue and Xylene Cyanole FF (Kodak) + EDTA (20 µl 0.5 M EDTA
pH 8.0/1 ml formamide)) were added to each 12.5 µl reaction. The entire reaction
was loaded onto a 9% Urea recovery gel (7.2 ml Urea stock 25% + 2ml buffer +
10.8 ml system diluent + 250 µl APS 10% + 10 µl TEMED). Electrophoresis was
carried out in 1× TBE at 500 V for 50 min followed by 650 V for 1 h and 50 min.
The bands were excised and the RNA was extracted by incubating the gel piece in
300 µl of elution buffer (0.3 M NaAcetate, 0.2% SDS) overnight at 4 °C.
300 µl Tris-saturated phenol were added to the liquid. The samples were
centrifuged for 10 min at 4 °C. The top aqueous layer was transferred to a fresh
tube and 1 ml of 100% EtOH were added to precipitate the RNA. After incubation
at −80 °C for> 30 min the samples were centrifuged for 30 min at 4 °C. The pellet
was air-dried for 5 min at room temperature and resuspended in 10 µl nuclease-
free H2O. The RNA was quantiﬁed by scintillation measurement using a Beckman
LS 6000SC scintillator. The RNA was stored at −20 °C until further use.
In vitro splicing assay. Ten fmol of 32P-labeled, m7G-capped T7 transcripts were
spliced in a 20-µl reaction as described50. Splicing reactions contained 1.56 mM
MgCl2, 32 mM HEPES, 0.5 mM ATP and 20 mM creatine phosphate, 1.3% PVA,
40% HeLa nuclear extract, and 1× buffer D (20 mM HEPES-KOH pH 8, 25%
glycerol, 1.5 mM MgCl2, 0.2 mM PMSF, 0.5 mM DTT, 0.6 M KCl). After incuba-
tion for 3 h at 30 °C, reactions were quenched with 10 volumes of splicing stop
solution (100 mM Tris pH 7.5, 10 mM EDTA, 1% SDS, 150 mM NaCl, 300 mM
NaAc). The RNA was extracted using phenol, ethanol precipitated, and analyzed by
denaturing PAGE and autoradiography.
RNA-sequencing. PNN 1–46 cells (Coriell) derived from a type 1 SMA patient
were treated with SMN-C3 at 500 nM and with NVS-SM1 at 24 nM for 24 h. RNA
was extracted with the RNeasy Mini Kit (Qiagen Inc., USA). Template DNA
molecules suitable for sequencing were prepared from 400 ng of total RNA using
the TruSeq Stranded mRNA Library Preparation Kit (Illumina Inc., San Diego,
CA) according to manufacturer’s instructions. After 14 cycles of PCR ampliﬁcation,
the size distribution of the barcoded DNA libraries was estimated by electro-
phoresis on Agilent High Sensitivity Bioanalyzer microﬂuidic chips. Minimum
sizes of ampliﬁed libraries were determined as> 200 nucleotides and average sizes
of ~300 nucleotides. Libraries were quantiﬁed using the KAPA Library Quantiﬁ-
cation Kit (Kapa Biosystems, Boston, MA). Libraries were pooled at equimolar
concentrations, spiked with 1% PhiX control library, and diluted to 20 pM prior to
loading onto the ﬂow cell of an Illumina HiSeq 2500 instrument (Illumina Inc., San
Diego, CA) for both clustering and sequencing. Libraries were extended and bridge
ampliﬁed to create single sequence clusters using the HiSeq PE Cluster Kit v4 cBot
HS (Illumina Inc., San Diego, CA). The ﬂow cell carrying ampliﬁed clusters was
then sequenced in high output run mode with 51 cycles for read 1, 7 cycles for the
barcode index and 51 cycles for read 2 using the HiSeq SBS Kit v4 chemistry
(Illumina Inc., San Diego, CA). 2 × 50-bp paired-end reads were generated with
~53 million read pairs per sample. Real-time image analysis and base calling was
performed on the HiSeq 2500 with the HiSeq Control Software v2.2.37. CASAVA
software version 1.8.2 was used for demultiplexing and production of FASTQ
sequence ﬁles.
The RNA-sequencing data from this study has been deposited at the NCBI
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under the accession
number GSE86001.
NMR spectroscopy. NMR spectroscopy measurements were performed on a
Bruker AV-III 500MHz (Bruker) and AV-III HD 900MHz (Bruker) both
equipped with cryo-probes. RNA oligonucleotides were purchased (Microsynth
AG), resuspended in water and precipitated with butanol to remove traces of small
molecules resulting from the chemical synthesis. In order to form the duplex
between the 5′-end of U1 (5′-AUACψψACCUG-3′) and the 5′-splice site of SMN2
(5′-GGAGUAAGUCU-3′), both oligonucleotides were mixed in equimolar
amounts in the NMR buffer (MES 10 mM pH 5.5, 50 mM NaCl, 10% D20) at ﬁnal
concentration of 400 µM, annealed to 90 °C and cooled down to room temperature.
The RNA duplex resonances were assigned by using 2D 1H–1H homonuclear and
natural abundance 2D 1H–13C HSQC experiments recorded at 283 K. After
assignment of the RNA resonances, distance constraints were derived from the
analysis of the NOESY spectra and used to model the RNA duplex using a
simulated annealing procedure. The chemical shifts and the coordinates of the
atomic models have been deposited into the BMRB and PDB under the following
accession numbers 34171 and 5OR0, respectively. The oligonucleotide corre-
sponding to ESE2 (5′-AAAAAGAAGGAAGG-3′) was also dissolved in the NMR
buffer at the same concentration. The three molecules, SMN-C5, SMN-C7, and
NVS-SM1 were resuspended in the NMR buffer at a ﬁnal concentration of 4 mM.
To monitor the interaction between the RNA duplex and the three molecules,
NMR titrations were performed at 298 K by adding the small molecule into the
RNA sample. The RNA resonances were monitored by recording 1D 1H and 2D
1H–1H TOCSY spectra for the following RNA:ligand molar ratios 1:0, 1:0.5, 1:1,
1:1.5, 1:2, 1:3, 1:4, and 1:5. In addition, natural abundance 2D 1H–13C HSQC was
recorded for the free form of the RNA and after addition of one molar equivalent of
SMN-C5. To monitor the interaction between ESE2 and the three small molecules,
NMR titrations were performed at 310 K in order to prevent oligomerization of the
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RNA. RNA resonances were monitored by recording 1D1H spectra for the fol-
lowing RNA:ligand molar ratios 1:0, 1:0.5, 1:1, 1:1.5, 1:2, 1:3, 1:4, and 1:5. The U1-C
zinc ﬁnger (1–61) was expressed in fusion with a GST tag and puriﬁed by afﬁnity
chromatography. After cleavage of the GST tag, U1-C zinc ﬁnger was further
puriﬁed by size exclusion chromatography in HEPES 10 mM pH 7.2, 100 mM
NaCl, 10 mM ZnSO4, and DTT 5 mM. U1-C was then complexed to the RNA
duplex U1-5′ss and further titrated by SMN-C5. NMR titrations were performed at
298 K by adding the small molecule into the protein–RNA sample. Protein–RNA
complexes of Tra2-β1 and hnRNP G RRMs bound to the RNA molecules 5′-
AAGAAC-3′ and 5′-GACAAA-3′ (Microsynth AG) were formed at a ratio of 1:1
by adding the RNA into the protein sample in their NMR buffer (50 mM L-Glu,
50 mM L-Arg, 0.05% β-mercaptoethanol, 20 mM NaHPO4, pH 5.5), respectively.
2D1H–15N HSQC spectra were then recorded in the absence and in the presence of
molecules at a protein–RNA complex:molecule ratio of 1:5. All NMR spectra were
recorded at 313 K.
Data availability. All relevant data are available from the authors upon request.
The RNAseq data are published and available at the NCBI Gene Expression
Omnibus (GEO) with accession number GSE86001. The chemical shifts and the
coordinates of the atomic models from the NMR data are published and available
in BMRB with BMRB entry number 34171 and PDB with PDB ID 5OR0.
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